All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 2021 ASCO Annual Meeting, the ALL Hub spoke with Guru Subramanian Guru Murthy, Medical College of Wisconsin, Milwaukee, US. We asked, What are the main advances in patient care that we are seeing with novel agents for leukemia?
What are the main advances in patient care that we are seeing with novel agents for leukemia?
Guru Murthy evaluates data on new targeted agents for ALL, including blinatumomab, an anti-CD19 bispecific antibody, and inotuzumab, an anti-CD22 antibody-drug conjugate. He also focuses on a new treatment for Philadelphia chromosome-positive ALL, using trial data investigating a chemotherapy-free approach that combined blinatumomab and ponatinib, a tyrosine kinase inhibitor (TKI).
Current recommendations for therapy-related toxicity management in ALL
Despite the great clinical advances in the field of acute lymphoblastic leukemia (ALL), novel therapies have led to the emergence of unique toxicities that need to be...
Updated results from the D-ALBA trial of dasatinib plus blinatumomab in newly diagnosed adult Ph+ ALL
The outcomes of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) are historically poor; however, they have...
Subscribe to get the best content related to ALL delivered to your inbox